C4 Therapeutics (NASDAQ: CCCC) net income
C4 Therapeutics reported a net loss of $105.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $105.3m. Earnings per share were −$1.27.
C4 Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$105.0m | — | −292.1% | −$1.27 |
| 2024 | −$105.3m | — | −296.0% | −$1.52 |
| 2023 | −$132.5m | — | −638.3% | −$2.67 |
| 2022 | −$128.2m | — | −412.2% | −$2.62 |
| 2021 | −$83.9m | — | −183.2% | −$1.82 |
| 2020 | −$66.3m | — | — | −$5.83 |
| 2019 | −$34.1m | — | — | −$31.03 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
C4 Therapeutics net income compared with its sector
By net income for its latest fiscal year, C4 Therapeutics ranks 340th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of C4 Therapeutics, −292.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 338th | Enliven Therapeutics | −$103.7m | — |
| 339th | Nkarta | −$104.1m | — |
| 340th | C4 Therapeutics | −$105.0m | −292.1% |
| 341st | Capricor Therapeutics | −$105.0m | — |
| 342nd | Oruka Therapeutics | −$105.4m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of C4 Therapeutics
- How much did C4 Therapeutics earn in fiscal 2025?
- C4 Therapeutics reported a net loss of $105.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $105.3m.
- What are the earnings per share of C4 Therapeutics?
- They were −$1.27 in fiscal 2025, compared with −$1.52 in fiscal 2024.
- Where does C4 Therapeutics rank in its sector by net income?
- It ranks 340th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for C4 Therapeutics come from?
- From the annual report (Form 10-K) that C4 Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that C4 Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on C4 Therapeutics: the C4 Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.